Moderate to Severe Glabellar Lines Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Active-Controlled (BOTOX®) and Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines in Subjects of Chinese Origin
This is a phase 3, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate the efficacy and safety of 50 units (U) of QM1114-DP for the treatment of moderate to severe GL in male and female subjects of Chinese origin. The study has been designed to test the superiority of QM1114-DP compared to placebo, and the non-inferior efficacy of QM1114-DP compared to onabotulinumtoxinA (BOTOX®), in improving the appearance of moderate to severe GL.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05743634 -
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT06151561 -
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
|
Phase 1 | |
| Completed |
NCT02353871 -
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Recruiting |
NCT06199336 -
A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT06354127 -
DWP450 for Treating Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03970876 -
Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
|
Phase 1/Phase 2 |